Impact of neutralizing antibodies against AAV is a key consideration in gene transfer to nonhuman primates
- 4 June 2018
- journal article
- letter
- Published by Springer Nature in Nature Medicine
- Vol. 24 (6) , 699
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Overcoming the Host Immune Response to Adeno-Associated Virus Gene Delivery Vectors: The Race Between Clearance, Tolerance, Neutralization, and EscapeAnnual Review of Virology, 2017
- Tmbim1 is a multivesicular body regulator that protects against non-alcoholic fatty liver disease in mice and monkeys by targeting the lysosomal degradation of Tlr4Nature Medicine, 2017
- Targeting CASP8 and FADD-like apoptosis regulator ameliorates nonalcoholic steatohepatitis in mice and nonhuman primatesNature Medicine, 2017
- Comparative Study of Liver Gene Transfer With AAV Vectors Based on Natural and Engineered AAV CapsidsMolecular Therapy, 2015
- AAV2 Gene Therapy Readministration in Three Adults with Congenital BlindnessScience Translational Medicine, 2012
- Impact of Pre-Existing Immunity on Gene Transfer to Nonhuman Primate Liver with Adeno-Associated Virus 8 VectorsHuman Gene Therapy, 2011
- Inverse zonation of hepatocyte transduction with AAV vectors between mice and non-human primatesMolecular Genetics and Metabolism, 2011
- Preexisting Immunity and Low Expression in Primates Highlight Translational Challenges for Liver-directed AAV8-mediated Gene TherapyMolecular Therapy, 2010
- Adeno-Associated Virus-Mediated Gene Transfer to Nonhuman Primate Liver Can Elicit Destructive Transgene-Specific T Cell ResponsesHuman Gene Therapy, 2009
- Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapyProceedings of the National Academy of Sciences, 2002